Immunomedics (IMMU) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Jefferies Upgrades Immunomedics (IMMU) to Buy
May 6, 2016 7:53 AM EDTJefferies upgraded Immunomedics (NASDAQ: IMMU) from Hold to Buy with a price target of $5.00 (from $1.50) as '132 continues to impress.
Analyst Chris Howerton, PhD commented, "In our view, '132 continues to demonstrate impressive clinical data in solid tumors. In particular, the recent... More
Immunomedics' (IMMU) IMMU-132 in TNBC Abstract Selected for Best of ASCO Program
May 2, 2016 12:18 PM EDTImmunomedics, Inc., (Nasdaq: IMMU) announced that the abstract on... More
